Published Date: 23-Sep-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
The Fabry Diseases market would showcase a CAGR of 6.1% during (2022 - 2028). A form of fat called globotriaosylceramide accumulates in the body's cells, causing Fabry disease, a genetic condition. This buildup, which starts in childhood, results in indications and syndromes that affect various body regions. Additional potentially fatal side effects of Fabry disease include increasing renal failure, heart problems, and stroke. Later-onset, milder types of illness that often just affect the heart, kidneys, or cerebral blood arteries affect some affected people.
The Enzyme Replacement Therapy market shows high market share in the Global Lysosomal Disease Treatment Market by Type of Therapy in 2021, thereby, achieving a market value of $6.6 Billion. It is because there is a sufficient supply of medications. Newly approved medicines by the leading companies in the market are the main drivers of market expansion. In order to treat the underlying enzyme shortage that contributes to Gaucher’s disease symptoms, ERT (enzyme replacement treatment) uses intravenous (IV) infusions (pronounced go-SHAY).
The Clinics market is anticipated to grow at a CAGR of 6.6% during (2022 - 2028). All patients with lysosomal storage disorders will receive integrated, personalized, multidisciplinary inpatient and outpatient care, as well as market-approved medications and access to clinical for focused treatment.
The North America market dominated the Global Lysosomal Disease Treatment Market by Region in 2021, thereby, achieving a market value of $4.1 Billion by 2028, growing at a CAGR of 5.2% during the forecast period. The Europe market is experiencing a CAGR of 5.7% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 7.3% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.
By Disease Type
By Type of Therapy
By End User
Unique Offerings from KBV Research